phase 2 trial - Robuta Search

https://www.newswire.ca/news-releases/pronai-reports-interim-data-from-wolverine-phase-2-trial-of-pnt2258-in-dlbcl-581947331.html ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company advancing targeted therapeutics for patients with cancer, today announced... phase 2 trial https://www.biospace.com/capricor-therapeutics-commences-dosing-patients-in-phase-2-trial-of-cap-1002-in-patients-with-severe-covid-19 Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with... Nov 24, 2020 - Capricor Therapeutics, Inc. announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002 phase 2 trial https://www.prweb.com/releases/lipella_pharmaceuticals_announces_enrollment_of_first_patient_in_phase_2_trial_in_interstitial_cystitis/prweb12924608.htm Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial... Pittsburgh, PA (PRWEB) August 27, 2015 -- Lipella Pharmaceuticals Inc. today announced dose administration for the first patient in a Phase-2 clinical study... phase 2 trial https://www.biospace.com/aprea-therapeutics-announces-positive-results-from-phase-2-trial-of-eprenetapopt-azacitidine-for-post-transplant-maintenance-therapy-in-tp53-mutant-mds-and-aml Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for... Jul 21, 2021 - Aprea Therapeutics, Inc. today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance... phase 2 trial https://www.globenewswire.com/news-release/2025/03/04/3036951/0/en/Strong-Proof-of-Concept-Data-from-Phase-2-Trial-of-PDE10A-Inhibitor-CPL-36-a-Novel-Once-Daily-Treatment-of-Levodopa-Induced-Dyskinesia-in-Parkinson-s-Disease.html Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS... proof of concept phase 2 trial strong data pde10a https://www.globenewswire.com/news-release/2021/07/06/2258496/0/en/FDA-Clears-Sorrento-Phase-2-Trial-Of-Non-Opioid-Product-Candidate-Resiniferatoxin-RTX-For-Treatment-of-the-Knee-Pain-in-Osteoarthritis-OA-Patients.html FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration... phase 2 trial fda clears sorrento non https://www.hmpgloballearningnetwork.com/site/neuro/news/phase-2-trial-finds-risdiplam-effective-and-safe-newborns-sma Phase 2 Trial Finds Risdiplam Effective and Safe in Newborns With SMA Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12... phase 2 trial https://www.mayo.edu/research/clinical-trials/cls-20484358?p=1 Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients - Mayo Clinic phase 2 trial https://www.biospace.com/apexigen-announces-positive-interim-results-from-phase-2-trial-evaluating-its-cd40-antibody-sotigalimab-in-combination-with-doxorubicin-in-patients-with-liposarcoma Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody,... Nov 14, 2022 - Apexigen, Inc. today announced topline data from an ongoing Phase 2 investigator sponsored trial in collaboration with Columbia University, evaluating... phase 2 trial https://www.biospace.com/tibotec-pharmaceuticals-ltd-discontinues-exploratory-phase-2-trial-with-tmc125 Tibotec Pharmaceuticals Ltd Discontinues Exploratory Phase 2 Trial With TMC125 - BioSpace phase 2 trial tibotec pharmaceuticals ltd exploratory https://www.globenewswire.com/news-release/2026/04/20/3277007/0/en/ALK-announces-successful-outcome-of-phase-2-trial-with-its-tablet-for-treatment-of-peanut-allergy-demonstrating-early-onset-of-efficacy.html ALK announces successful outcome of phase 2 trial with its Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population... phase 2 trial alk announces successful outcome https://www.biospace.com/ritter-pharmaceuticals-inc-abstract-on-rp-g28-s-phase-2-trial-selected-for-oral-presentation-at-b-digestive-disease-week-2012-b Ritter Pharmaceuticals, Inc.' Abstract on RP-G28's Phase 2 Trial Selected for Oral Presentation at... https://www.biospace.com/press-releases/allarity-therapeutics-announces-expansion-of-phase-2-clinical-trial-to-accelerate-development-of-stenoparib-in-advanced-ovarian-cancer Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of... phase 2 clinical trial expansion of https://www.fiercebiotech.com/biotech/big-pharma-backed-storm-blows-56m-fundraise-launches-phase-2-sarcoma-trial Storm secures $56M fundraise, launches phase 2 sarcoma trial Apr 16, 2026 - Former Fierce 15 honoree Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial for sarcoma patients. phase 2 storm secures 56m fundraise https://www.businesswire.com/news/home/20201201005539/en/Turnstone-Biologics-Announces-First-Patients-Enrolled-in-Phase-12-Clinical-Trial-Evaluating-RIVAL-01-For-the-Treatment-of-Solid-Tumors Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial Evaluating... Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of engineered viral immunotherapies, today announced enrollment ... https://www.biospace.com/press-releases/lyell-immunopharma-announces-oral-presentation-of-new-clinical-data-from-the-phase-1-2-trial-of-lyl314-for-the-treatment-of-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-2025 Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of... https://finviz.com/news/340669/biogen-announces-second-positive-phase-2-litifilimab-trial-in-cutaneous-lupus-erythematosus-at-2026-american-academy-of-dermatology-annual-meeting-showing-a-significant-reduction-in-skin-disease-activity Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026... Stock screener for investors and traders, financial visualizations. https://www.businesswire.com/news/home/20250122193446/en/Humanetics-Corporation-Announces-Positive-Phase-2-Clinical-Trial-Results-in-COVID-19-Study-Aimed-at-Improving-Pulmonary-Function Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at... This release details preliminary results from a phase II clinical trial of BIO 300. phase 2 clinical trial